Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells

Circulation

Volumn 106, Issue 23, 2002, Pages 2888-2893

  Schönbeck, Uwe ^a   Gerdes, Norbert ^a   Varo, Nerea ^a   Reynolds, Rebecca S ^a   Horton, Daniel B ^a   Bavendiek, Udo ^a   Robbie, Linda ^a   Ganz, Peter ^a   Kinlay, Scott ^a   Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Inflammation; Statins

Indexed keywords

ATORVASTATIN; CD40 ANTIGEN; CD40 LIGAND; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVALONIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIGENS, CD40; BLOOD COAGULATION; CD40 LIGAND; CELLS, CULTURED; COHORT STUDIES; CORONARY STENOSIS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; MALE; MICE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PHAGOCYTES; PYRIDINES; PYRROLES; RNA, MESSENGER; SIMVASTATIN;

EID: 0037016008     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000043029.52803.7B     Document Type: Article

References (35)

1. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
2. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999;340:115-126.
3. Reul RM, Fang JC, Denton MD, et al. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation. 1997;64:1765-1774.
4. Mach F, Schönbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U SA. 1997;94:1931-1936.
5. Gaweco AS, Wiesner RH, Yong S, et al. CD40L (CD154) expression in human liver allografts during chronic ductopenic rejection. Liver Transpl Surg. 1999;5:1-7.
6. Afford SC, Randhawa S, Eliopoulos AG, et al. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection. J Exp Med. 1999;189:441-446.
7. Malik N, Greenfield BW, Wahl AF, et al. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol. 1996;156:3952-3960.
8. Zhou L, Stordeur P, de Lavareille A, et al. CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost. 1998;79:1025-1028.
9. Miller DL, Yaron R, Yellin MJ. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol. 1998;63:373-379.
10. Slupsky JR, Kalbas M, Willuweit A, et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost. 1998;80:1008-1014.
11. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4-43.
12. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
13. Mach F, Schönbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200-203.
14. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-1316.
15. Schönbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A. 2000;97:7458-7463.
16. Lutgens E, Cleutjens KB, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A. 2000;97:7464-7469.
17. Graf D, Muller S, Korthauer U, et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25:1749-1754.
18. Ludewig B, Henn V, Schroder JM, et al. Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J Immunol. 1996;26:3137-3143.
19. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614-620.
20. Schönbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-2268.
21. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079-1082.
22. Dangas G, Smith DA, Unger AH. et al. Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost. 2000;83:688-692.
23. Ni W, Egashira K, Kataoka C, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res. 2001;89:415-421.
24. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446-1452.
25. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
26. Schönbeck U, Mach F, Sukhova GK, et al. Expression of stromelysin-3 in atherosclerotic lesions: Regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med. 1999;189:843-853.
27. 2-antiplasmin and plasminogen activator inhibitor 1 (PA1-1) in the inhibition of clot lysis. Thromb Haemost. 1993;70:301-306.
28. Libby P, Aikawa M, Schönbeck U. Cholesterol and atherosclerosis. Biochim Biophys Acta. 2000;1529:299-309.
29. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
30. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization. Circulation. 1998;97:2433-2444.
31. Hakkinen T, Karkola K, Yla-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions: Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD 16 (Fc gammaRIII). Virchows Arch. 2000;437:396-405.
32. Henn V, Slupsky JR, Grate M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
33. Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood. 2002;99:2612-2614.
34. Garlichs CD, John S, Schmeisser A, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001;104:2395-2400.
35. 3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.